South Korea · Delayed Price · Currency is KRW CellBion Company Description
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products.
Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage.
It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications.
The company was founded in 2010 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2010 |
| Industry | Pharmaceutical Preparations |
| Employees | 57 |
| CEO | Kweon Kim |
Contact Details
Address: 103, Daehak-ro Seoul, 03080 South Korea | |
| Phone | 82 2 743 3311 |
| Website | cellbion.co.kr |
Stock Details
| Ticker Symbol | 308430 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kweon Kim | Chief Executive Officer |